EUA to Corbevax for 12-18 Age Group

February 22, 2022

A vaccine manufacturer based in Hyderabad, Biological E has received emergency use authorization (EUA) from the drug regulator of India for its Covid-19 vaccine for children aged 12 to 18.

Overview:

Biological E’s Corbevax vaccine was earlier approved by the Drugs Controller General of India for limited usage in adults during emergency situations in 2019. Based on the results that were seen during the ongoing Phase II and Phase III clinical research, the Drugs Controller General of India has given its approval for the vaccine to be used in teenagers who are aged between 12 to 18 years.

Currently, the nation’s COVID-19 vaccination programme includes children aged fifteen to eighteen years, with only Covaxin from Bharat Biotech approved for this age range.

An advance payment of Rs 1500 crores was made by the central government to reserve 30 crore doses of vaccine.

About Corbevax

Corbevax is the country’s first indigenously made receptor-binding domain (RBD) protein subunit vaccine against Covid-19.

Via intramuscular route, this vaccine is administered to the person. Two doses are to be taken which are scheduled 28 days apart. This vaccine has to be stored at a temperature range of 2 to 8 degrees Celsius.

About Biological E

Biological E is an Indian biopharmaceutical and biotechnology company which is located in Hyderabad. This company focuses on the production of low-cost vaccines. This biopharmaceutical company was founded in the year 1953 and Mahima Datla is the Marketing Director of the company.

« Previous Post Next Post »